Partial
Mostly Aligned
Patient Risk:
Low
Summary
The provided AI-generated response aligns with FDA labeling on indications (nerve pain and seizures) but omits key safety domains (contraindications, pregnancy/pediatric safety) and dosing safety. It also asserts caffeine-related interactions that are not supported by the label excerpts. No explicit boxed warning is identified in the provided sections; full labeling should be consulted to confirm boxed warnings if present.
Category Scores
Accurate Statements
Lyrica (pregabalin) is indicated for the management of neuropathic pain associated with diabetic peripheral neuropathy and for adjunctive therapy for partial-onset seizures.
Indications include diabetic peripheral neuropathy neuropathic pain and adjunctive therapy for partial-onset seizures; label also includes postherpetic neuralgia, fibromyalgia, spinal cord injury neuropathic pain.
Warning guidance includes consulting a doctor for unusual symptoms.
Warnings and precautions include seeking medical advice for concerning symptoms.
Unsupported Statements
Caffeine interactions between Lyrica and caffeine are discussed and clinically significant.
Label excerpts provided do not discuss caffeine; 7 Drug Interactions discusses only certain antiepileptics; no caffeine interactions.
High doses of caffeine with Lyrica cause dizziness.
Label does not link caffeine to Lyrica adverse effects; dizziness is listed as an adverse reaction to Lyrica but not attributed to caffeine.
Low to moderate caffeine up to 200 mg/day is safe with Lyrica.
No caffeine-specific safety thresholds in label.
Contradictions
Important Omissions
Contraindications
Importance:
High
Pregnancy and lactation safety
Importance:
High
Pediatric use and dosing
Importance:
High
Boxed warnings
Importance:
High
Dosing safety (renal dosing, max dose)
Importance:
Moderate
Caffeine interaction data (no label support)
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Safety statements present are generic; unsupported caffeine interaction claims reduce risk, but omissions of critical safety domains pose safety considerations if user relies on this information without consulting the label.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Missing contraindication, pregnancy/pediatric safety, boxed warnings, and dosing safety details; caffeine interaction claims not label-supported.
Suggested Improvement
Align with label: add explicit contraindications, pregnancy and pediatric safety sections, boxed warnings if any, and proper dosage safety details. Remove unsupported caffeine interaction claims and avoid general caffeine safety assertions.